Accuray Inc Dossier
Qualitative Analysis
Business overview
Accuray Incorporated (NASDAQ: ARAY) is a specialized medical technology company that designs, develops, manufactures, and sells advanced radiation therapy and radiosurgery systems. The company's core product offerings are centered around two primary platforms: the CyberKnife System, a robotic stereotactic radiosurgery (SRS) and stereotactic body radiation therapy (SBRT) system known for its real-time motion tracking and precision, and the Radixact System, a helical intensity-modulated radiation therapy (IMRT) platform. Accuray operates globally, serving hospitals, academic medical centers, and specialty oncology clinics. It competes in a highly consolidated market dominated by larger players such as Varian Medical Systems (a Siemens Healthineers company) and Elekta AB.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
A multi-phase turnaround plan launched in December 2025 to improve annualized operating profitability by approximately $25 million. Key actions include organizational realignment, rightsizing the cost structure (including a 15% global workforce reduction), outsourcing, and sales enablement.
Expected impact: Expected to deliver $25 million in annualized operating profitability improvements, with $12 million targeted for FY2026 (already achieved $10 million through Q3 FY2026).
Introduction and commercial rollout of the Accuray Stellar Solution, an all-in-one adaptive radiotherapy platform built on the Radixact Treatment Delivery System, designed to make adaptive treatments simple, fast, and practical.
Expected impact: Aims to drive product adoption in the U.S. and global markets by simplifying adaptive radiotherapy workflows and integrating real-time motion tracking.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Formalizes and expands a long-term collaborative relationship to support clinical research, education, training, and the development of adaptive therapies using Accuray's Stellar platform.
Terms: Not disclosed
A strategic joint venture with China National Nuclear Corporation (CNNC) to manufacture and sell localized radiation oncology systems (such as the Tomo C System) in the rapidly growing Chinese market.
Terms: Joint venture structure where Accuray holds an equity interest to address local procurement preferences in China.